Multiplex Immunoassay System Enters into the Special Approval Procedure of SMPA

Illumaxbio received a notice from the MDE of Sichuan Medical Prouducts Administration on November 11th, agreeing that the Automatic Multiplex Immunoassay System of Illumaxbio should be reviewed in accordance with the special review procedure for innovative medical devices (IVD). It is reported that Illumaxbio is the first IVD company in Sichuan Province to enter the special review procedure for medical devices in 2021. The worldwide first Single Automatic Multiplex Immunoassay System of Illumaxbio, with ingenious design for clinical needs, breaking through the technological blockade of many core components, and the whole chain is independent and controllable.